


Amendments to the claims:

This listing of claims will replace all previous versions, and listings, of claims in this application.

Listing of Claims:

1.(currently amended) A compound having the formula



wherein:

R¹ is H, NO₂, halo, NR⁶R⁷, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, C₁₋₆haloalkylO, R⁶OC₀₋₆alkyl, R⁶CO, R⁶OCO or CONR⁶R⁷;

m is 0, 1, 2 or 3;

R² is NO₂, halo, NR⁶R⁷, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, C₁₋₆haloalkylO, cyano, R⁶OC₀₋₆alkyl, R⁶CO, R⁶OCO, R⁶CONR⁷, R⁶R⁷NCO, R⁸SO₂, R⁸SO₂HN, arylC₀₋₆alkyl or heteroarylC₀₋₆alkyl;

R³ and R⁹ are each independently H or C₁₋₄alkyl;

p is 0, 1 or 2;

n is 0, 2, 3 or 4;

R⁵ is C₁₋₁₀alkyl, C₆₋₁₀arylC₀₋₆alkyl, C₃₋₇cycloalkylC₀₋₆alkyl or C₅₋₆heteroarylC₀₋₆alkyl, whereby any aryl, heteroaryl or cycloalkyl may be fused with aryl, heteroaryl,

C₃₋₇cycloalkyl or C₃₋₇heterocycloalkyl, and which R⁵ may be substituted with one or more A;

A is H, OH, NO₂, cyano, R⁶CO, R⁶O(CO), halo, C₁₋₆alkyl, NR⁶R⁷, C₁₋₆haloalkyl, C₁₋₆haloalkylO, R⁶OC₀₋₆alkyl, hydroxyC₁₋₆alkyl, R⁸SO₂, R⁸SO₂HN, C₅₋₆arylO or CONR⁶R⁷;

R⁶ and R⁷ are each independently H or C₁₋₆alkyl; and

R⁸ is NR⁶R⁷ or C₁₋₄alkyl,

~~or salts, solvates or solvated salts or a salt, solvate or solvated salt thereof.~~

2.(currently amended) [[The]] A compound according to claim 1, wherein:

R^1 is H, halo, NR^6R^7 , $C_{1-6}alkyl$, $C_{1-6}haloalkyl$, $C_{1-6}haloalkylO$, $R^6OC_{0-6}alkyl$, R^6CO , R^6OCO or $CONR^6R^7$;

m is 0 or 1;

R^2 is NO_2 , halo, NR^6R^7 , $C_{1-6}alkyl$, $C_{1-6}haloalkyl$, cyano, R^6OCO , R^6CONR^7 , R^8SO_2 , R^8SO_2HN or heteroaryl $C_{0-6}alkyl$;

R^3 and R^9 are each independently H or $C_{1-4}alkyl$;

p is 0;

n is 0;

R^5 is $C_{1-10}alkyl$, $C_{6-10}arylC_{0-6}alkyl$ or $C_{5-6}heteroarylC_{0-6}alkyl$, whereby any aryl may be fused with $C_{3-7}cycloalkyl$ or $C_{3-7}heterocycloalkyl$, and which R^5 may be substituted with one or more A;

A is H, cyano, halo, NO_2 , $C_{1-6}alkyl$, NR^6R^7 , $C_{1-6}haloalkyl$, $C_{1-6}haloalkylO$, $R^6OC_{0-6}alkyl$, hydroxy $C_{1-6}alkyl$, R^8SO_2 or $C_{5-6}arylO$;

R^6 and R^7 are each independently H or $C_{1-6}alkyl$; and

R^8 is NR^6R^7 or $C_{1-4}alkyl$,

~~or salts, solvates or solvated salts or a salt, solvate or solvated salt thereof.~~

3.(currently amended) [[The]] A compound according to claim 1, wherein

R^2 is NO_2 , halo, NR^6R^7 , $C_{1-4}alkyl$, $C_{1-4}haloalkyl$, $C_{1-2}haloalkylO$, cyano, $R^6OC_{0-4}alkyl$, R^6CO , R^6OCO , R^6CONR^7 , R^6R^7NCO , R^8SO_2 , R^8SO_2HN , aryl $C_{0-6}alkyl$ and heteroaryl and wherein

R^6 and R^7 are each independently H or $C_{1-4}alkyl$ and

R^8 is NR^6R^7 or $C_{1-3}alkyl$.

4.(currently amended) [[The]] A compound according to claim 1, wherein R^2 is $[[\text{nitro}]] NO_2$.

5.(currently amended) [[The]] A compound according to claim 1, wherein R^5 is phenyl, which may be substituted with one or more A.

6.(currently amended) [[The]] A compound according to claim 5, wherein A is selected from the group ~~comprising~~ consisting of halo, alkoxy, haloalkoxy, haloalkyl, alkyl, alkanol, cyano, phenoxy, alkylsulfonyl and (di)alkylamino.

7.(currently amended) [[The]] A compound according to claim 1, wherein A is selected from the group consisting of fluoro, iodo, chloro, bromo, methoxy, ethoxy, trifluoromethyl, difluoromethoxy, trifluoromethoxy, tetrafluoroethoxy, methyl, ethyl, propyl, butyl, hydroxyethyl, cyano, phenoxyethylsulfonyl and dimethylamino.

8.(currently amended) The compounds A compound selected from the group consisting of:

*N-(3-Fluoro-4-methoxy-phenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)-acetamide,*
*N-[2-Fluoro-4-(trifluoromethyl)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,*
*N-(3-Chloro-4-iodophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,*
*N-(3-Chloro-4-methoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,*
*N-[3-(Difluoromethoxy)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,*
*N-[3-Methoxy-5-(trifluoromethyl)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,*
*N-(3,5-Difluorophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,*
*2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[4-(trifluoromethoxy)phenyl]acetamide,*
*2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]acetamide,*
*N-(4-*tert*-Butylphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,*
*N-[3-(1-Hydroxyethyl)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,*
*2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[4-(trifluoromethyl)phenyl]acetamide,*
*N-(3-Chlorophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,*
*N-Hexyl-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,*
*N-(3,4-Difluorophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,*
*N-(4-Cyanophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,*
*N-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,*
*N-(2-Bromobenzyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,*
*2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)benzyl]acetamide,*
*N-(4-Methylpyridin-2-yl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,*
*N-(3-Cyanophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,*
*N-(3,5-Dimethoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,*
*N-(4-Methoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,*
*N-(3-Ethoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,*

N-(3,4-Dimethoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-(3,4,5-trimethoxyphenyl)acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethoxy)phenyl]acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-(3-phenoxyphenyl)acetamide,
N-(4-Butylphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(2-Fluoro-4-iodophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[2-(trifluoromethoxy)phenyl]acetamide,
N-(4-Methoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-(2-phenoxyphenyl)acetamide,
N-(4-Bromo-2-fluorophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-[3-(Methylsulfonyl)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-[4-(Methylsulfonyl)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[4-(trifluoromethyl)benzyl]acetamide,
N-(4-*tert*-Butylbenzyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(2,3-dihydro-1*H*-inden-5-yl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[4-(trifluoromethoxy)benzyl]acetamide,
N-(4-Isopropylphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(3,4-Dimethylphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-1,3-Benzodioxol-5-yl-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-[3-Bromo-4-(trifluoromethoxy)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(3-Fluoro-2-methoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(3,5-dimethoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)propanamide,
N-(3-Ethoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)propanamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]propanamide,
N-(3,5-Dimethylphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(7-Bromo-1*H*-benzimidazol-1-yl)-*N*-(3,5-dimethoxyphenyl)acetamide,
2-(7-Bromo-1*H*-benzimidazol-1-yl)-*N*-(3-methoxyphenyl)acetamide,
2-(7-Bromo-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(7-Chloro-1*H*-benzimidazol-1-yl)-*N*-(3,5-dimethoxyphenyl)acetamide,
2-(7-Chloro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(7-Chloro-1*H*-benzimidazol-1-yl)-*N*-(4-methylphenyl)acetamide,
2-(7-Chloro-1*H*-benzimidazol-1-yl)-*N*-(2,3-dihydro-1*H*-inden-5-yl)acetamide,

2-(7-Methyl-1*H*-benzimidazol-1-yl)-N-(4-methylphenyl)acetamide,
N-(3,5-Dimethoxyphenyl)-2-(7-methyl-1*H*-benzimidazol-1-yl)acetamide,
2-(7-Methyl-1*H*-benzimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide,
N-(2,3-Dihydro-1*H*-inden-5-yl)-2-(7-methyl-1*H*-benzimidazol-1-yl)acetamide,
Methyl 1-{2-[(3,4-dimethylphenyl)amino]-2-oxoethyl}-1*H*-benzimidazole-7-carboxylate,
Methyl 1-[2-(2,3-dihydro-1*H*-inden-5-ylamino)-2-oxoethyl]-1*H*-benzimidazole-7-
carboxylate,
Methyl 1-{2-[(4-*tert*-butylbenzyl)amino]-2-oxoethyl}-1*H*-benzimidazole-7-carboxylate,
Methyl 1-(2-{[3-methoxy-5-(trifluoromethyl)phenyl]amino}-2-oxoethyl)-1*H*-benzimidazole-
7-carboxylate,
Methyl 1-{2-[(3,5-dimethoxyphenyl)amino]-2-oxoethyl}-1*H*-benzimidazole-7-carboxylate,
N-(3,5-Dimethoxyphenyl)-2-{7-[(dimethylamino)sulfonyl]-1*H*-benzimidazol-1-yl}acetamide,
2-{7-[(Dimethylamino)sulfonyl]-1*H*-benzimidazol-1-yl}-N-[3-
(trifluoromethyl)phenyl]acetamide,
N-(3,5-Dimethoxyphenyl)-2-[7-(propylsulfonyl)-1*H*-benzimidazol-1-yl]acetamide,
2-[7-(Propylsulfonyl)-1*H*-benzimidazol-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide,
N-[3-Methoxy-5-(trifluoromethyl)phenyl]-2-[7-(methylsulfonyl)-1*H*-benzimidazol-1-
yl]acetamide,
N-(3,5-Dimethoxyphenyl)-2-[7-(trifluoromethyl)-1*H*-benzimidazol-1-yl]acetamide,
N-(3,4-Dimethylphenyl)-2-[7-(trifluoromethyl)-1*H*-benzimidazol-1-yl]acetamide,
N-(4-*tert*-Butylbenzyl)-2-[7-(trifluoromethyl)-1*H*-benzimidazol-1-yl]acetamide,
N-(2,3-Dihydro-1*H*-inden-5-yl)-2-[7-(trifluoromethyl)-1*H*-benzimidazol-1-yl]acetamide,
2-(7-Cyano-1*H*-benzimidazol-1-yl)-N-(3,5-dimethoxyphenyl)acetamide,
2-(7-Cyano-1*H*-benzimidazol-1-yl)-N-(3-methoxyphenyl)acetamide,
2-(7-Cyano-1*H*-benzimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide,
2-(7-Cyano-1*H*-benzimidazol-1-yl)-N-(2,3-dihydro-1*H*-inden-5-yl)acetamide,
N-(2,3-Dihydro-1*H*-inden-5-yl)-2-(7-fluoro-1*H*-benzimidazol-1-yl)acetamide,
N-(3,5-Dimethoxyphenyl)-2-(7-fluoro-1*H*-benzimidazol-1-yl)acetamide,
N-(4-*tert*-Butylbenzyl)-2-(7-fluoro-1*H*-benzimidazol-1-yl)acetamide,
2-(7-Amino-1*H*-benzoimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide,
2-[7-(Acetylamino)-1*H*-benzoimidazol-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide,
2-{7-[(Methylsulfonyl)amino]-1*H*-benzoimidazol-1-yl}-N-[3-
(trifluoromethyl)phenyl]acetamide,

2-[7-(Dimethylamino)-1H-benzimidazol-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide,
2-[7-(Isopropylamino)-1H-benzimidazol-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide,
N-(3,5-Dimethoxyphenyl)-2-[7-(1H-tetrazol-5-yl)-1H-benzimidazol-1-yl]acetamide,
and
2-(6,7-Difluoro-1H-benzimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide,
~~or salts, solvates or solvated salts or a salt, solvate or solvated salt~~ thereof.

9.(currently amended) A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of the compound according to ~~any one of claims 1 to 8 claim 1~~, in association with one or more pharmaceutically acceptable diluents, excipients and/or inert carriers.

10. - 17.(cancelled)

18.(currently amended) A method of ~~treating~~ VR1 mediated disorders, and for ~~treatment of~~ acute and chronic pain disorders, acute and chronic neuropathic pain, acute and chronic inflammatory pain, and respiratory diseases, comprising ~~administering~~ administering to a mammal, ~~including man~~ in need of such treatment, a therapeutically effective amount of the compounds of formula I, according to ~~any one of claims 1 to 8 a~~ compound according to claim 1.

19.(currently amended) ~~Compounds selected from the group consisting of~~ A compound selected from the group consisting of:
(7-Nitro-1H-benzimidazol-1-yl)acetonitrile,
(7-Nitro-1H-benzimidazol-1-yl)acetic acid,
2-(7-Nitro-1H-benzimidazol-1-yl)propanenitrile,
2-(7-nitro-1H-benzimidazol-1-yl)propanoic acid,
2-[(2-Bromo-6-nitrophenyl)amino]ethanol,
2-[(2-Amino-6-bromophenyl)amino]ethanol,

2-(7-Bromo-1*H*-benzimidazol-1-yl)ethanol,
(7-Bromo-1*H*-benzimidazol-1-yl)acetic acid,
8-Chloro-3-oxo-3,4-dihydroquinoxaline-1(2*H*)-carbaldehyde,
2-[(2-Amino-6-chlorophenyl)amino]ethanol,
2-(7-Chloro-1*H*-benzimidazol-1-yl)ethanol,
(7-Chloro-1*H*-benzimidazol-1-yl)acetic acid,
(2-Methyl-6-nitrophenyl)formamide,
Ethyl *N*-formyl-*N*-(2-methyl-6-nitrophenyl)glycinate,
Ethyl *N*-(2-amino-6-methylphenyl)-*N*-formylglycinate,
(7-Methyl-1*H*-benzimidazol-1-yl)acetic acid,
2-[(2-Hydroxyethyl)amino]-3-nitrobenzoic acid,
Methyl 2-[(2-hydroxyethyl)amino]-3-nitrobenzoate,
Methyl 1-(2-hydroxyethyl)-1*H*-benzimidazole-7-carboxylate,
3-Carboxymethyl-3*H*-benzimidazole-4-carboxylic acid methyl ester,
2-Chloro-*N,N*-dimethyl-3-nitrobenzenesulfonamide,
2-[(2-Hydroxyethyl)amino]-*N,N*-dimethyl-3-nitrobenzenesulfonamide,
3-Amino-2-[(2-hydroxyethyl)amino]-*N,N*-dimethylbenzenesulfonamide,
1-(2-Hydroxyethyl)-*N,N*-dimethyl-1*H*-benzimidazole-7-sulfonamide,
(7-Dimethylsulfamoyl-benzimidazol-1-yl)-acetic acid,
2-Chloro-1-nitro-3-(propylsulfonyl)benzene,
2-{[2-Nitro-6-(propylsulfonyl)phenyl]amino}ethanol,
2-{[2-Amino-6-(propylsulfonyl)phenyl]amino}ethanol,
[7-(Propylsulfonyl)-1*H*-benzimidazol-1-yl]acetic acid,
[7-(Methylsulfonyl)-1*H*-benzimidazol-1-yl]acetic acid,
2-(7-(Methylsulfonyl)-1*H*-benzimidazol-1-yl)-ethanol,
2-{[2-Nitro-6-(trifluoromethyl)phenyl]amino}ethanol,
2-{[2-amino-6-(trifluoromethyl)phenyl]amino}ethanol,
2-[7-(Trifluoromethyl)-1*H*-benzimidazol-1-yl]ethanol,
[7-(Trifluoromethyl)-1*H*-benzimidazol-1-yl]acetic acid,
2-[(2-hydroxyethyl)amino]-3-nitrobenzonitrile,
1-(2-hydroxyethyl)-1*H*-benzimidazole-7-carbonitrile,
(7-Cyano-1*H*-benzimidazol-1-yl)acetic acid,
2-[(2-Fluoro-6-nitrophenyl)amino]ethanol,

2-(7-Fluoro-1*H*-benzoimidazol-1-yl)ethanol, and
(7-Fluoro-1*H*-benzimidazol-1-yl)acetic acid[[],,].

20.(cancelled)

21.(currently amended) ~~The compounds selected from the group consisting of A compound selected from the group consisting of:~~

2-(1*H*-Benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]propanamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-(3-chloro-4-fluorophenyl)acetamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-(3-fluoro-4-methylphenyl)acetamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-(3,4-difluorophenyl)acetamide,
2-(4-Methyl-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(4,5-Difluoro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-[3-(dimethylamino)phenyl]acetamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-(4-*tert*-butylphenyl)acetamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)benzyl]acetamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-(4-chlorobenzyl)acetamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-(3,5-dimethoxyphenyl)acetamide,
3-(1*H*-Benzimidazol-1-yl)-*N*-(4-*tert*-butylphenyl)propanamide,
4-(1*H*-Benzimidazol-1-yl)-*N*-(4-*tert*-butylphenyl)butanamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-(2-methyl-1,3-benzothiazol-5-yl)acetamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(4-Amino-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(5-Fluoro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(6-Fluoro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(4-Nitro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide, and
2-(1*H*-Benzimidazol-1-yl)-*N*-heptylacetamide,
~~or salts, solvates or solvated salts or a salt, solvate or solvated salt thereof.~~

22.(currently amended) ~~The compounds selected from the group consisting A~~
compound selected from the group consisting of:

2-(1*H*-Indol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(5-Fluoro-1*H*-indol-3-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide, and
2-(1-Methyl-1*H*-indol-3-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
~~or salts, solvates or solvated salts or a salt, solvate or solvated salt thereof.~~

23.(new) The method according to claim 18, wherein said VR1 mediated disorder is selected from: arthritis, fibromyalgia, low back pain, post-operative pain, visceral pain, chronic pelvic pain, cystitis, irritable bowel syndrome, pancreatitis, ischemia, sciatica, diabetic neuropathy, multiple sclerosis, interstitial cystitis and pain related to interstitial cystitis, HIV neuropathy, asthma, cough and inflammatory bowel disease, gastro-esophageal reflux disease, psoriasis, cancer, emesis, urinary incontinence or hyperactive bladder.

24.(new) The method according to claim 18, wherein said mammal is a human.